🟢 CervoMed is trading 7.3% up in after-hours trading after extending cash runway through Q3 2027

CervoMed is trading at $3.07 (+7.34%) after reporting second-quarter 2026 results and corporate updates.

• Cash runway extends through Q3 2027, supported by $20.5 million in June financings.
• Management is prioritizing a strategic partnership for a pivotal Phase 3 DLB trial.
• Net loss widened to $6.6 million, while grant revenue fell $1.8 million year over year.